BEERSE, Belgium--(BUSINESS WIRE)--Janssen-Cilag International NV today announced that its next generation protease inhibitor (PI) OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C (CHC), in combination with other medicinal products, which includes1: View full press release here.
Help employers find you! Check out all the jobs and post your resume.
